Blueprint Medicines Corp
NASDAQ:BPMC
Balance Sheet
Balance Sheet Decomposition
Blueprint Medicines Corp
Blueprint Medicines Corp
Balance Sheet
Blueprint Medicines Corp
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
2
|
47
|
163
|
52
|
400
|
68
|
114
|
685
|
210
|
120
|
71
|
102
|
|
| Cash Equivalents |
2
|
47
|
163
|
52
|
400
|
68
|
114
|
685
|
210
|
120
|
71
|
102
|
|
| Short-Term Investments |
0
|
0
|
0
|
162
|
273
|
426
|
370
|
187
|
267
|
825
|
639
|
513
|
|
| Total Receivables |
0
|
0
|
3
|
4
|
0
|
0
|
23
|
25
|
37
|
37
|
43
|
78
|
|
| Accounts Receivables |
0
|
0
|
3
|
4
|
0
|
0
|
23
|
25
|
37
|
37
|
43
|
78
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
22
|
30
|
21
|
14
|
|
| Other Current Assets |
1
|
1
|
4
|
3
|
12
|
6
|
10
|
22
|
18
|
35
|
33
|
36
|
|
| Total Current Assets |
2
|
48
|
170
|
220
|
686
|
500
|
517
|
928
|
554
|
1 047
|
808
|
743
|
|
| PP&E Net |
1
|
2
|
7
|
6
|
24
|
30
|
111
|
102
|
121
|
115
|
116
|
101
|
|
| PP&E Gross |
1
|
2
|
7
|
6
|
24
|
30
|
111
|
102
|
121
|
115
|
116
|
101
|
|
| Accumulated Depreciation |
1
|
2
|
2
|
3
|
5
|
9
|
14
|
20
|
25
|
31
|
38
|
48
|
|
| Long-Term Investments |
0
|
0
|
0
|
54
|
0
|
0
|
64
|
678
|
558
|
134
|
57
|
248
|
|
| Other Long-Term Assets |
0
|
0
|
2
|
2
|
6
|
11
|
15
|
11
|
20
|
55
|
69
|
88
|
|
| Total Assets |
4
N/A
|
50
+1 117%
|
179
+259%
|
283
+58%
|
716
+153%
|
540
-25%
|
708
+31%
|
1 718
+143%
|
1 252
-27%
|
1 350
+8%
|
1 049
-22%
|
1 180
+12%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
1
|
1
|
3
|
2
|
4
|
3
|
5
|
4
|
8
|
3
|
5
|
7
|
|
| Accrued Liabilities |
1
|
4
|
6
|
12
|
31
|
52
|
96
|
114
|
130
|
142
|
140
|
146
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
1
|
2
|
3
|
3
|
2
|
0
|
0
|
0
|
0
|
17
|
30
|
44
|
|
| Other Current Liabilities |
0
|
0
|
7
|
12
|
7
|
5
|
6
|
13
|
12
|
22
|
40
|
64
|
|
| Total Current Liabilities |
3
|
7
|
19
|
29
|
43
|
60
|
107
|
131
|
150
|
183
|
215
|
261
|
|
| Long-Term Debt |
2
|
7
|
4
|
2
|
0
|
0
|
0
|
0
|
0
|
122
|
209
|
343
|
|
| Other Liabilities |
0
|
0
|
12
|
40
|
49
|
61
|
137
|
118
|
132
|
530
|
495
|
277
|
|
| Total Liabilities |
6
N/A
|
15
+159%
|
35
+141%
|
70
+100%
|
92
+32%
|
121
+32%
|
243
+101%
|
248
+2%
|
282
+13%
|
835
+197%
|
919
+10%
|
881
-4%
|
|
| Equity | |||||||||||||
| Common Stock |
40
|
115
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
42
|
82
|
135
|
208
|
356
|
598
|
945
|
631
|
1 275
|
1 833
|
2 340
|
2 407
|
|
| Additional Paid In Capital |
1
|
3
|
279
|
421
|
980
|
1 017
|
1 412
|
2 107
|
2 250
|
2 358
|
2 474
|
2 709
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
5
|
4
|
10
|
3
|
4
|
|
| Total Equity |
2
N/A
|
35
N/A
|
144
+307%
|
213
+48%
|
624
+193%
|
419
-33%
|
464
+11%
|
1 470
+217%
|
971
-34%
|
515
-47%
|
131
-75%
|
299
+129%
|
|
| Total Liabilities & Equity |
4
N/A
|
50
+1 117%
|
179
+259%
|
283
+58%
|
716
+153%
|
540
-25%
|
708
+31%
|
1 718
+143%
|
1 252
-27%
|
1 350
+8%
|
1 049
-22%
|
1 180
+12%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
26
|
26
|
27
|
33
|
44
|
44
|
49
|
58
|
59
|
60
|
61
|
64
|
|